MA52308A - Procédés et intermédiaires pour la préparation d'antagonistes c5ar - Google Patents

Procédés et intermédiaires pour la préparation d'antagonistes c5ar

Info

Publication number
MA52308A
MA52308A MA052308A MA52308A MA52308A MA 52308 A MA52308 A MA 52308A MA 052308 A MA052308 A MA 052308A MA 52308 A MA52308 A MA 52308A MA 52308 A MA52308 A MA 52308A
Authority
MA
Morocco
Prior art keywords
intermediaries
preparing
methods
c5ar antagonists
c5ar
Prior art date
Application number
MA052308A
Other languages
English (en)
Inventor
Pingchen Fan
Jaroslaw Kalisiak
Antoni Krasinski
Rebecca Lui
Jay Powers
Sreenivas Punna
Hiroko Tanaka
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA52308A publication Critical patent/MA52308A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
MA052308A 2014-09-29 2015-09-28 Procédés et intermédiaires pour la préparation d'antagonistes c5ar MA52308A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462057107P 2014-09-29 2014-09-29

Publications (1)

Publication Number Publication Date
MA52308A true MA52308A (fr) 2021-02-24

Family

ID=55583729

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052308A MA52308A (fr) 2014-09-29 2015-09-28 Procédés et intermédiaires pour la préparation d'antagonistes c5ar

Country Status (19)

Country Link
US (5) US9745268B2 (fr)
EP (2) EP3200791B1 (fr)
JP (1) JP6898229B6 (fr)
KR (2) KR20230149873A (fr)
CN (2) CN113121415A (fr)
AU (2) AU2015324111B2 (fr)
BR (1) BR112017006232B1 (fr)
CA (2) CA2960733C (fr)
DK (1) DK3200791T3 (fr)
ES (2) ES2926828T3 (fr)
IL (1) IL251061B (fr)
MA (1) MA52308A (fr)
MX (2) MX368492B (fr)
NZ (2) NZ730123A (fr)
PL (1) PL3200791T3 (fr)
PT (1) PT3200791T (fr)
RU (1) RU2712233C2 (fr)
SG (1) SG11201702185UA (fr)
WO (1) WO2016053890A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2381778T1 (sl) 2008-12-22 2016-10-28 Chemocentryx, Inc. Antagonisti C5AR
ES2632975T3 (es) * 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
AU2018359214A1 (en) * 2017-10-30 2020-04-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators
SG11202011961YA (en) 2018-06-07 2020-12-30 Chemocentryx Inc Dosing and effect of c5a antagonist with anca-associated vasculitis
BR112021010285A2 (pt) 2018-11-30 2021-08-17 Chemocentryx, Inc. formulações de cápsula
KR102207333B1 (ko) * 2019-09-09 2021-01-27 성균관대학교산학협력단 4중 연속 고리 화합물의 신규한 제조방법
CN114867473A (zh) 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2021092286A1 (fr) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Forme amorphe d'un récepteur de constituant c5a du complément
WO2022078269A1 (fr) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Forme cristalline d'avacopan, son procédé de préparation et son utilisation
WO2022263263A1 (fr) 2021-06-16 2022-12-22 Sandoz Ag Forme cristalline d'avacopan
EP4137133A1 (fr) 2021-08-19 2023-02-22 Sandoz AG Forme cristalline d'avacopan
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技（苏州）有限公司 一种Avacopan及其中间体的制备方法
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
WO2023158722A2 (fr) 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processus de préparation d'avacopan et de ses intermédiaires

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
JP2002523448A (ja) 1998-08-28 2002-07-30 サイオス インコーポレイテッド ｐ３８−αキナーゼのインヒビター
RU2197288C2 (ru) 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
EP1278743A4 (fr) 2000-05-05 2003-05-14 Smithkline Beecham Corp Nouveaux anti-infectieux
US7105567B2 (en) 2000-08-10 2006-09-12 Mitsubishi Pharma Corporation 3-substituted urea derivatives and medicinal use thereof
US7855297B2 (en) 2000-09-14 2010-12-21 Mitsubishi Tanabe Pharma Corporation Amide derivatives and medicinal use thereof
CN1454086A (zh) 2000-09-29 2003-11-05 神经能质公司 高亲和性小分子C5a受体调节物
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
DE10293175D2 (de) 2001-07-19 2004-07-01 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges unter Berücksichtigung eines Fluidverlustes
WO2003015819A1 (fr) 2001-08-17 2003-02-27 Tanox, Inc. Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
HUP0401900A3 (en) 2001-09-21 2005-08-29 Sanofi Aventis 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2479928A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
CA2480082A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
JP2005536533A (ja) * 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2004110996A1 (fr) 2003-06-19 2004-12-23 Pfizer Products Inc. Antagoniste de nk1
WO2005007087A2 (fr) 2003-07-03 2005-01-27 Neurogen Corporation Derives (heterocycloalkyl)methyle substitues de type azole utilises comme modulateurs des recepteurs c5a
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2005267289A1 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP1621536A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase
WO2006071958A1 (fr) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Composes utilises comme antagonistes du recepteur de la chimiokine
KR20070113233A (ko) 2005-02-18 2007-11-28 아스트라제네카 아베 항균성 피페리딘 유도체
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007051062A2 (fr) 2005-10-28 2007-05-03 Chemocentryx, Inc. Dihydropyridines substituees et leurs methodes d'utilisation
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
MX340784B (es) 2006-03-15 2016-07-26 Alexion Pharma Inc Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna.
WO2008022060A2 (fr) 2006-08-14 2008-02-21 Novartis Ag composés organiques et leurs utilisations
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
JP2010531873A (ja) 2007-06-29 2010-09-30 トレント ファーマシューティカルズ リミテッド Ｈｓｐ誘導剤としての新規の置換ピペリドン
CA2737219C (fr) 2008-08-11 2017-02-28 Tracy Keller Analogues d'halofuginone pour l'inhibition d'arnt synthetases et leurs utilisations
WO2010025510A1 (fr) 2008-09-03 2010-03-11 Xenome Ltd Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
SI2381778T1 (sl) 2008-12-22 2016-10-28 Chemocentryx, Inc. Antagonisti C5AR
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2011035143A2 (fr) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Procédés et compositions pour inhiber des maladies et des états à médiation par rho
ES2632975T3 (es) * 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
KR20150033652A (ko) 2012-06-20 2015-04-01 노파르티스 아게 보체 경로 조절제 및 그의 용도
WO2014180961A1 (fr) 2013-05-08 2014-11-13 Novo Nordisk A/S Utilisation d'antagonistes de c5ar
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
EP4262800A1 (fr) 2020-12-21 2023-10-25 ChemoCentryx, Inc. Traitement de la glomérulopathie à c3 à l'aide d'un inhibiteur de c5a

Also Published As

Publication number Publication date
KR20170085492A (ko) 2017-07-24
SG11201702185UA (en) 2017-04-27
US10266492B2 (en) 2019-04-23
ES2802428T3 (es) 2021-01-19
IL251061A0 (en) 2017-04-30
US20180072668A1 (en) 2018-03-15
MX2019011911A (es) 2019-11-25
US20190276402A1 (en) 2019-09-12
US9745268B2 (en) 2017-08-29
AU2015324111B2 (en) 2021-04-01
CN106999481A (zh) 2017-08-01
PT3200791T (pt) 2020-05-06
NZ730123A (en) 2023-05-26
RU2017114960A (ru) 2018-11-07
NZ767823A (en) 2023-05-26
US10532982B2 (en) 2020-01-14
WO2016053890A1 (fr) 2016-04-07
EP3200791A4 (fr) 2018-06-13
US11845729B2 (en) 2023-12-19
BR112017006232B1 (pt) 2022-10-11
KR20230149873A (ko) 2023-10-27
US20230008966A1 (en) 2023-01-12
EP3200791B1 (fr) 2020-04-22
MX2017003789A (es) 2017-08-02
DK3200791T3 (da) 2020-05-25
EP3682879A1 (fr) 2020-07-22
CA2960733A1 (fr) 2016-04-07
EP3682879B1 (fr) 2022-08-03
JP2017529378A (ja) 2017-10-05
BR112017006232A2 (pt) 2017-12-12
AU2021204209B2 (en) 2022-10-06
AU2021204209A1 (en) 2021-07-15
US20160090357A1 (en) 2016-03-31
CA3220371A1 (fr) 2016-04-07
JP6898229B6 (ja) 2021-07-28
MX368492B (es) 2019-10-04
JP6898229B2 (ja) 2021-07-07
RU2712233C2 (ru) 2020-01-27
AU2015324111A1 (en) 2017-04-06
ES2926828T3 (es) 2022-10-28
US20200354320A1 (en) 2020-11-12
RU2017114960A3 (fr) 2019-04-10
KR102593431B1 (ko) 2023-10-23
IL251061B (en) 2019-09-26
CN113121415A (zh) 2021-07-16
CA2960733C (fr) 2024-01-09
PL3200791T3 (pl) 2020-08-10
CN106999481B (zh) 2021-04-16
EP3200791A1 (fr) 2017-08-09

Similar Documents

Publication Publication Date Title
MA52308A (fr) Procédés et intermédiaires pour la préparation d'antagonistes c5ar
HK1243104A1 (zh) 抗fgfr2/3抗體及其使用方法
HK1249023A1 (zh) Pd-l1("程序性死亡配體1")抗體
ZA201605154B (en) Insecticidal proteins and methods for their use
HK1253306A1 (zh) 抗ntb-a抗體及相關組合物和方法
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
EP3148729A4 (fr) Microparticules revêtues d'un hydrure, et procédés pour leur fabrication
ZA201702161B (en) Insecticidal proteins and methods for their use
MA52906A (fr) Procédé de préparation d'amg 416
ZA201703443B (en) Oral rehydration composition and methods thereof
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d'utilisation
IL247315A0 (en) Anti-acth antibodies and their uses
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI562334B (en) Semiconductor device and methods for forming the same
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
FR3025729B1 (fr) Ensemble pour le broyage d'echantillons biologiques
EP3542143C0 (fr) Rhéomètre et procédé d'utilisation de celui-ci
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
FR3033251B1 (fr) Treuil d'evacuation en va-et-vient
FI3183568T3 (fi) Laite objektien fraktioimiseksi ja fraktiointimenetelmä
FR3022149B1 (fr) Systeme d'haltere reglable
FR3019480B1 (fr) Dispositif anti-vibreur pour l'usinage d'arbre
FR3040381B1 (fr) Systeme pour le prelevement d'articles en stock